Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland.
Gastro-oesophageal reflux disease (GERD) can be effectively treated pharmacologically or surgically.
As GERD is often a chronic condition, we compared the long-term costs of medical and surgical management.
The medical regimens were ranitidine (150 or 300 mg/day), omeprazole (20 or 40 mg/day), and lansoprazole (30 mg/day), with costs calculated for total life expectancy after diagnosis and for one-third of that time.
Costs for open or laparoscopic surgery (Nissen fundoplication) included pre-and post-operative investigations, sick leave, and calculated financial loss due to fatal outcome.
Costs were lowest with ranitidine, 150 mg/day, for one-third of the patient's lifetime and highest with lifelong omeprazole, 40 mg/daily.
The cost of open or laparoscopic operation was less than that of lifelong daily treatment with proton pump inhibitors or ranitidine, 300 mg daily.
In Finland, antireflux surgery for GERD is cheaper than lifetime treatment with proton pump inhibitors.
Mots-clés Pascal : Reflux gastrooesophagien, Etude comparative, Coût, Traitement, Chimiothérapie, Plastie, Intervention Nissen, Etude statistique, Homme, Appareil digestif pathologie, Oesophage pathologie, Economie santé, Chirurgie
Mots-clés Pascal anglais : Gastroesophageal reflux, Comparative study, Costs, Treatment, Chemotherapy, Plasty, Nissen operation, Statistical study, Human, Digestive diseases, Esophageal disease, Health economy, Surgery
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0450148
Code Inist : 002B13A03. Création : 03/02/1998.